Woolf Alan D, Erdman Andrew R, Nelson Lewis S, Caravati E Martin, Cobaugh Daniel J, Booze Lisa L, Wax Paul M, Manoguerra Anthony S, Scharman Elizabeth J, Olson Kent R, Chyka Peter A, Christianson Gwenn, Troutman William G
American Association of Poison Control Centers, Washington, District of Columbia, USA.
Clin Toxicol (Phila). 2007;45(3):203-33. doi: 10.1080/15563650701226192.
A review of U.S. poison center data for 2004 showed over 12,000 exposures to tricyclic antidepressants (TCAs). A guideline that determines the conditions for emergency department referral and prehospital care could potentially optimize patient outcome, avoid unnecessary emergency department visits, reduce healthcare costs, and reduce life disruption for patients and caregivers. An evidence-based expert consensus process was used to create the guideline. Relevant articles were abstracted by a trained physician researcher. The first draft of the guideline was created by the lead author. The entire panel discussed and refined the guideline before distribution to secondary reviewers for comment. The panel then made changes based on the secondary review comments. The objective of this guideline is to assist poison center personnel in the appropriate prehospital triage and management of patients with suspected ingestions of TCAs by 1) describing the manner in which an ingestion of a TCA might be managed, 2) identifying the key decision elements in managing cases of TCA ingestion, 3) providing clear and practical recommendations that reflect the current state of knowledge, and 4) identifying needs for research. This guideline applies to ingestion of TCAs alone. Co-ingestion of additional substances could require different referral and management recommendations depending on their combined toxicities. This guideline is based on the assessment of current scientific and clinical information. The panel recognizes that specific patient care decisions may be at variance with this guideline and are the prerogative of the patient and the health professionals providing care, considering all the circumstances involved. This guideline does not substitute for clinical judgment. Recommendations are in chronological order of likely clinical use. The grade of recommendation is in parentheses. 1) Patients with suspected self-harm or who are the victims of malicious administration of a TCA should be referred to an emergency department immediately (Grade D). 2) Patients with acute TCA ingestions who are less than 6 years of age and other patients without evidence of self-harm should have further evaluation including standard history taking and determination of the presence of co-ingestants (especially other psychopharmaceutical agents) and underlying exacerbating conditions, such as convulsions or cardiac arrhythmias. Ingestion of a TCA in combination with other drugs might warrant referral to an emergency department. The ingestion of a TCA by a patient with significant underlying cardiovascular or neurological disease should cause referral to an emergency department at a lower dose than for other individuals. Because of the potential severity of TCA poisoning, transportation by EMS, with close monitoring of clinical status and vital signs en route, should be considered (Grade D). 3) Patients who are symptomatic (e.g., weak, drowsy, dizzy, tremulous, palpitations) after a TCA ingestion should be referred to an emergency department (Grade B). 4) Ingestion of either of the following amounts (whichever is lower) would warrant consideration of referral to an emergency department: an amount that exceeds the usual maximum single therapeutic dose or an amount equal to or greater than the lowest reported toxic dose. For all TCAs except desipramine, nortriptyline, trimipramine, and protriptyline, this dose is >5 mg/kg. For despiramine it is >2.5 mg/kg; for nortriptyline it is >2.5 mg/kg; for trimipramine it is >2.5 mg/kg; and for protriptyline it is >1 mg/kg. This recommendation applies to both patients who are naïve to the specific TCA and to patients currently taking cyclic antidepressants who take extra doses, in which case the extra doses should be added to the daily dose taken and then compared to the threshold dose for referral to an emergency department (Grades B/C). 5) Do not induce emesis (Grade D). 6) The risk-to-benefit ratio of prehospital activated charcoal for gastrointestinal decontamination in TCA poisoning is unknown. Prehospital activated charcoal administration, if available, should only be carried out by health professionals and only if no contraindications are present. Do not delay transportation in order to administer activated charcoal (Grades B/D). 7) For unintentional poisonings, asymptomatic patients are unlikely to develop symptoms if the interval between the ingestion and the initial call to a poison center is greater than 6 hours. These patients do not need referral to an emergency department facility (Grade C). 8) Follow-up calls to determine the outcome for a TCA ingestions ideally should be made within 4 hours of the initial call to a poison center and then at appropriate intervals thereafter based on the clinical judgment of the poison center staff (Grade D). 9) An ECG or rhythm strip, if available, should be checked during the prehospital assessment of a TCA overdose patient. A wide-complex arrhythmia with a QRS duration longer than 100 msec is an indicator that the patient should be immediately stabilized, given sodium bicarbonate if there is a protocol for its use, and transported to an emergency department (Grade B). 10) Symptomatic patients with TCA poisoning might require prehospital interventions, such as intravenous fluids, cardiovascular agents, and respiratory support, in accordance with standard ACLS guidelines (Grade D). 11) Administration of sodium bicarbonate might be beneficial for patients with severe or life-threatening TCA toxicity if there is a prehospital protocol for its use (Grades B/D). 12) For TCA-associated convulsions, benzodiazepines are recommended (Grade D). 13) Flumazenil is not recommended for patients with TCA poisoning (Grade D).
对美国毒物控制中心2004年数据的回顾显示,三环类抗抑郁药(TCA)暴露病例超过12,000例。制定确定急诊科转诊条件和院前护理条件的指南可能会优化患者预后,避免不必要的急诊科就诊,降低医疗成本,并减少对患者及其护理人员生活的干扰。采用循证专家共识流程制定该指南。相关文章由一名经过培训的医师研究人员进行摘要。指南初稿由第一作者撰写。在将指南分发给二级审阅者征求意见之前,整个小组对其进行了讨论和完善。然后,小组根据二级审阅意见进行了修改。本指南的目的是通过以下方式协助毒物控制中心人员对疑似摄入TCA的患者进行适当的院前分诊和管理:1)描述TCA摄入的处理方式;2)确定TCA摄入病例管理中的关键决策要素;3)提供反映当前知识水平的清晰实用建议;4)确定研究需求。本指南仅适用于单独摄入TCA的情况。同时摄入其他物质可能需要根据其联合毒性制定不同的转诊和管理建议。本指南基于对当前科学和临床信息的评估。小组认识到,具体的患者护理决策可能与本指南不一致,在考虑所有相关情况时,这是患者和提供护理的卫生专业人员的特权。本指南不能替代临床判断。建议按可能的临床使用时间顺序排列。推荐等级在括号内。1)疑似自我伤害或TCA恶意给药受害者的患者应立即转诊至急诊科(D级)。2)6岁以下急性摄入TCA的患者以及无自我伤害证据的其他患者应进行进一步评估,包括标准病史采集以及确定是否同时摄入其他物质(尤其是其他精神药物)和潜在的加重病情,如惊厥或心律失常。同时摄入TCA和其他药物可能需要转诊至急诊科。患有严重基础心血管或神经系统疾病的患者摄入TCA时,应比其他个体在更低剂量时转诊至急诊科。由于TCA中毒的潜在严重性,应考虑由急救医疗服务(EMS)转运,并在途中密切监测临床状态和生命体征(D级)。3)摄入TCA后出现症状(如虚弱、嗜睡、头晕、震颤、心悸)的患者应转诊至急诊科(B级)。4)摄入以下任何一种量(取较低者)均应考虑转诊至急诊科:超过通常最大单次治疗剂量的量或等于或大于最低报告中毒剂量的量。对于除地昔帕明、去甲替林、曲米帕明和普罗替林之外的所有TCA,此剂量>5mg/kg。对于地昔帕明,此剂量>2.5mg/kg;对于去甲替林,此剂量>2.5mg/kg;对于曲米帕明,此剂量>2.5mg/kg;对于普罗替林,此剂量>1mg/kg。本建议适用于初次接触特定TCA的患者以及当前正在服用环类抗抑郁药且额外服药的患者,在后一种情况下,应将额外剂量加到每日服用剂量中,然后与转诊至急诊科的阈值剂量进行比较(B/C级)。5)不要催吐(D级)。6)TCA中毒时院前使用活性炭进行胃肠道去污的风险效益比尚不清楚。如有可用,院前活性炭给药仅应由卫生专业人员进行,且仅在无禁忌证时进行。不要为了给予活性炭而延迟转运(B/D级)。7)对于非故意中毒,如果摄入与首次致电毒物控制中心之间的间隔大于6小时,无症状患者不太可能出现症状。这些患者无需转诊至急诊科(C级)。8)理想情况下,应在首次致电毒物控制中心后4小时内对TCA摄入情况进行随访电话,然后根据毒物控制中心工作人员的临床判断在适当间隔后进行随访(D级)。9)如有条件,在对TCA过量患者进行院前评估时应检查心电图或心律图。QRS时限超过100毫秒的宽QRS波心律失常表明患者应立即稳定病情,如有使用碳酸氢钠的方案应给予碳酸氢钠,并转运至急诊科(B级)。10)有症状的TCA中毒患者可能需要根据标准的高级心血管生命支持(ACLS)指南进行院前干预,如静脉输液、心血管药物和呼吸支持(D级)。11)如果有院前使用碳酸氢钠的方案,对于严重或危及生命的TCA毒性患者,给予碳酸氢钠可能有益(B/D级)。12)对于TCA相关惊厥,推荐使用苯二氮䓬类药物(D级)。13)不推荐对TCA中毒患者使用氟马西尼(D级)。